European Academy of Allergy and Clinical Immunology

KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update

Retrieved on: 
Thursday, September 7, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Injection, Attack, Stifel, Hereditary angioedema, NDA, Medication, Research, European Academy of Allergy and Clinical Immunology, HAE, Patient, Physician, Commercial, KALV, FDA, Conference, D, Pharmaceutical industry

(NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the first fiscal quarter ended July 31, 2023.

Key Points: 
  • (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the first fiscal quarter ended July 31, 2023.
  • First Fiscal Quarter Financial Results:
    Revenue: No revenue was recognized for the three months ended July 31, 2023 or July 31, 2022.
  • The increase in R&D expenses during the quarter primarily reflects the ongoing Phase 3 KONFIDENT trial for sebetralstat and increased personnel costs.
  • The decrease in the net cash and marketable securities position was due to cash consumption from operating expenses.

Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023
Volunteering, CSU, Lirentelimab, Atopic dermatitis, Research, European Academy of Allergy and Clinical Immunology, Antibody, Metabolism, Patient, Investment, SAN, Allergy, Depreciation, Immunoglobulin E, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry

Research and development expenses were $27.3 million in the second quarter of 2023 compared to $34.4 million in the second quarter of 2022, a decrease of $7.1 million.

Key Points: 
  • Research and development expenses were $27.3 million in the second quarter of 2023 compared to $34.4 million in the second quarter of 2022, a decrease of $7.1 million.
  • Allakos reported a net loss of $35.1 million in the second quarter of 2023 compared to $49.1 million in the second quarter of 2022.
  • Net loss per basic and diluted share was $0.41 for the second quarter of 2023 compared to $0.90 in the second quarter of 2022.
  • Allakos ended the second quarter of 2023 with $221.1 million in cash, cash equivalents and investments resulting in a net decrease in cash, cash equivalents and investments of $31.5 million during the second quarter of 2023.

Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, August 8, 2023
Well, Hypersensitivity, Rockefeller University, Survival, G&A, Omalizumab, Angioedema, KIT, ILT4, Patient, Prurigo nodularis, R, Quality of life, Allergy, Research, European Academy of Allergy and Clinical Immunology, Eosinophil, Prurigo, Neoplasm, PD-1, Kinetics, Skin, Safety, D, Index, Eosinophilic esophagitis, CSU, Contingency, B cell, Cell, Hives, PCE, MTD, Itch, Therapy, Myelocyte, Dysphagia, Clinical trial, Esophagus, EAACI, PN, Physician, UCT, SD, Rare-earth element, Pharmaceutical industry, Vaccine, Beauty salon, Cryptocurrency, Video game, Dermatology

HAMPTON, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Key Points: 
  • - Phase 2 CSU enrollment completed; topline data by YE 2023 -
    HAMPTON, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.
  • In July 2023, Celldex announced that enrollment to the CSU study had been completed.
  • CSU EAACI 2023 Data Summary:
    At EAACI 2023 , data were presented on the complete 24 week experience for all patients.
  • In May 2023, Celldex announced that the first patient had been dosed in the Phase 1 study of CDX-585.

Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 7, 2023
Attack, Association of International Accountants, Bank statement, Hereditary angioedema, Foresite Capital, Record, EAACI, Research, Allergy, Trial of the century, HAE, Deficiency, Investigational New Drug, European Academy of Allergy and Clinical Immunology, Patient, Administration, Research and development, General Atlantic, R, FDA, Angioedema, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Book, Food, Safety, International Accounting Standards Board, Vaccine, Pharmaceutical industry, Cryptocurrency

Pharvaris anticipates submitting the results of this nonclinical study to the FDA by the end of 2023.

Key Points: 
  • Pharvaris anticipates submitting the results of this nonclinical study to the FDA by the end of 2023.
  • R&D expenses were €14.7 million for the quarter ended June 30, 2023, compared to €13.7 million for the quarter ended June 30, 2022.
  • G&A expenses were €7.8 million for the quarter ended June 30, 2023, compared to €7.7 million for the quarter ended June 30, 2022.
  • Pharvaris is a Foreign Private Issuer and prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board.

Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Thursday, August 3, 2023
NTLA, Intellia Therapeutics, Retirement, Investigational New Drug, Patient, Ventilator-associated lung injury, Cardiomyopathy, Cell engineering, Disease, Tissue, Gene editing, Research, European Academy of Allergy and Clinical Immunology, NK, AATD, Liver, FDA, IND, D, DNA, SERPINA1, HAE, ATM, Therapy, CRISPR, Liver disease, KLKB1, CTA, EAACI, TTR, ATTR, A1AT, Physician, Amyloidosis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Female, Pharmaceutical industry, Medical imaging, Fine chemical, Rare-earth element, Vaccine, Video game

The Company plans to present additional data from the ATTRv-PN arm of the Phase 1 study by year-end 2023.

Key Points: 
  • The Company plans to present additional data from the ATTRv-PN arm of the Phase 1 study by year-end 2023.
  • Collaboration Revenue: Collaboration revenue decreased by $0.4 million to $13.6 million during the second quarter of 2023, compared to $14.0 million during the second quarter of 2022.
  • G&A Expenses: General and administrative expenses increased by $8.5 million to $30.7 million during the second quarter of 2023, compared to $22.1 million during the second quarter of 2022.
  • Net Loss: The Company’s net loss was $123.7 million for the second quarter of 2023, compared to $100.7 million during the second quarter of 2022.

SIAF: Disrupted epithelial barriers as a predictor of severe COVID-19 development

Retrieved on: 
Monday, July 10, 2023
Permeability (electromagnetism), DNA, University of Zurich, Asthma, Obesity, Dysbiosis, University, TRANCE, Diabetes, AXIN1, Infection, COVID-19, CXCL10, End organ damage, Atopic dermatitis, Research, European Academy of Allergy and Clinical Immunology, Biomarker, Microbiota, Swiss Institute Contemporary Art New York, Journal, HIV disease progression rates, DSM-IV codes, Patient, Swiss Institute of Allergy and Asthma Research, AREG, Reading, Conditional sentence, CXCL11, Death, Allergen, Maharashtra University of Health Sciences, Autoimmunity, Rheumatoid arthritis, Inflammation, CLEC4C, Vaccine, Allergy

DAVOS, Switzerland, July 10, 2023 /PRNewswire/ -- According to the epithelial barrier theory, disruption of epithelial barriers by environmental and toxic agents triggers microbial dysbiosis, bacterial translocation to subepithelial areas and local or systemic immune/inflammatory response to environmental agents, allergens and microbes. Such events have been implicated in the development of chronic conditions like allergic, autoimmune, and metabolic diseases, such as diabetes, obesity, rheumatoid arthritis, allergies, asthma, atopic dermatitis. In severe cases of COVID-19, characteristic features include hyperinflammation, hyperactivated immune responses (referred to as the cytokine storm), cellular infiltration, and organ damage.

Key Points: 
  • In severe cases of COVID-19, characteristic features include hyperinflammation, hyperactivated immune responses (referred to as the cytokine storm), cellular infiltration, and organ damage.
  • The compromised epithelial barriers in the mucosas, particularly in gut mucosa facilitates the translocation of microbiota and their secreted metabolites, thus initiating or exacerbating inflammatory cascades in many inflammatory diseases.
  • The research group of epithelial biology in the Swiss Institute of Allergy and Asthma Research, associated with the University of Zurich, has been working on epithelial barriers for more than 20 years.
  • The authors analyzed the amount of bacterial DNA leakage to circulation and showed the link between disrupted epithelial barriers and an excessive inflammatory response.

SIAF: Disrupted epithelial barriers as a predictor of severe COVID-19 development

Retrieved on: 
Monday, July 10, 2023
Permeability (electromagnetism), DNA, University of Zurich, Asthma, Obesity, Dysbiosis, University, TRANCE, Diabetes, AXIN1, Infection, COVID-19, CXCL10, End organ damage, Atopic dermatitis, Research, European Academy of Allergy and Clinical Immunology, Biomarker, Microbiota, Swiss Institute Contemporary Art New York, Journal, HIV disease progression rates, DSM-IV codes, Patient, Swiss Institute of Allergy and Asthma Research, AREG, Reading, Conditional sentence, CXCL11, Death, Allergen, Maharashtra University of Health Sciences, Autoimmunity, Rheumatoid arthritis, Inflammation, CLEC4C, Vaccine, Allergy

DAVOS, Switzerland  , July 9, 2023 /PRNewswire/ -- According to the epithelial barrier theory, disruption of epithelial barriers by environmental and toxic agents triggers microbial dysbiosis, bacterial translocation to subepithelial areas and local or systemic immune/inflammatory response to environmental agents, allergens and microbes. Such events have been implicated in the development of chronic conditions like allergic, autoimmune, and metabolic diseases, such as diabetes, obesity, rheumatoid arthritis, allergies, asthma, atopic dermatitis. In severe cases of COVID-19, characteristic features include hyperinflammation, hyperactivated immune responses (referred to as the cytokine storm), cellular infiltration, and organ damage.

Key Points: 
  • In severe cases of COVID-19, characteristic features include hyperinflammation, hyperactivated immune responses (referred to as the cytokine storm), cellular infiltration, and organ damage.
  • The compromised epithelial barriers in the mucosas, particularly in gut mucosa facilitates the translocation of microbiota and their secreted metabolites, thus initiating or exacerbating inflammatory cascades in many inflammatory diseases.
  • The research group of epithelial biology in the Swiss Institute of Allergy and Asthma Research, associated with the University of Zurich, has been working on epithelial barriers for more than 20 years.
  • The authors analyzed the amount of bacterial DNA leakage to circulation and showed the link between disrupted epithelial barriers and an excessive inflammatory response.

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

Retrieved on: 
Friday, July 7, 2023
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Attack, International Society of Sculptors, Painters and Gravers, Hereditary angioedema, Clinical trial, NDA, ODT, EAACI, G&A, Research, European Academy of Allergy and Clinical Immunology, Angioedema, ISTH, Thrombosis, Public expenditure, Congress, HAE, Patient, PMDA, Mouse, KALV, FDA, Safety, D, Pharmaceutical industry, Lancet

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal year ended April 30, 2023.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal year ended April 30, 2023.
  • “We have made a great deal of progress over the last fiscal year in the development of sebetralstat,” said Andrew Crockett, Chief Executive Officer of KalVista.
  • Research and development expenses were $80.3 million for the fiscal year ended April 30, 2023, compared to $70.2 million for the prior fiscal year.
  • General and administrative expenses were $30.6 million for the fiscal year ended April 30, 2023, compared to $26.4 million for the prior fiscal year.

New Analysis of MRI Findings Shows UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Subclinical Spinal Cord Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Retrieved on: 
Friday, June 30, 2023
Research, Radiology, Pharmaceutical, Optical, Medical Devices, Clinical Trials, Science, Biotechnology, Neurology, FDA, Other Science, Health, EAN, OLP, Civil service commission, ANVISA, Spinal cord, RCP, European Academy of Neurology, Prognosis, NMOSD, MRI, Congress, European Academy of Allergy and Clinical Immunology, European Commission, Patient, Physician, Optic nerve, Brazilian Health Regulatory Agency, Horizon, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Disease, Pharmaceutical industry, Medical imaging

This analysis is being presented at the 9th Congress of the European Academy of Neurology (EAN), July 1-4 in Budapest.

Key Points: 
  • This analysis is being presented at the 9th Congress of the European Academy of Neurology (EAN), July 1-4 in Budapest.
  • Results from this post-hoc analysis demonstrate that UPLIZNA effectively reduced the formation of subclinical MRI lesions, while also showing an association between subclinical spinal cord lesions and future attacks.
  • Subsequent MRI findings showed that the formation of these lesions decreased as treatment with UPLIZNA continued.
  • Interestingly, these findings showed that subclinical lesions were associated with domain-specific attacks in the following year.

Allergy Standards Ltd (ASL) Showcases Research at EAACI and Cements its Footprint in Europe at Healthy Buildings 2023

Retrieved on: 
Wednesday, June 28, 2023
Allergy, Asthma, Paint, USGBC, Built environment, IAQ, EAACI, Research, European Academy of Allergy and Clinical Immunology, Certification, Congress, Literature, ASL, Pharmaceutical industry, Medical device

DUBLIN, June 28, 2023 /PRNewswire-PRWeb/ -- Allergy Standards Ltd (ASL), a leading international certification body, proudly announces its successful participation in two prominent European conferences: the European Academy of Allergy and Clinical Immunology (EAACI) Congress and Healthy Buildings 2023 Europe. ASL's groundbreaking research on the relationship between carpets and asthma and allergies received enthusiastic reception from industry professionals and experts.

Key Points: 
  • DUBLIN, June 28, 2023 /PRNewswire-PRWeb/ -- Allergy Standards Ltd (ASL), a leading international certification body, proudly announces its successful participation in two prominent European conferences: the European Academy of Allergy and Clinical Immunology (EAACI) Congress and Healthy Buildings 2023 Europe.
  • ASL's groundbreaking research on the relationship between carpets and asthma and allergies received enthusiastic reception from industry professionals and experts.
  • ASL's Science Lead, Dr. GrAinne Cunniffe, represented the company at the 2023 EAACI Congress held in Hamburg, Germany.
  • ASL also participated recently in Healthy Buildings 2023 Europe, a leading conference focused on emerging trends in indoor air quality (IAQ).